Previous close | 52.11 |
Open | 52.91 |
Bid | 58.59 x 900 |
Ask | 58.44 x 800 |
Day's range | 52.74 - 60.56 |
52-week range | 41.33 - 277.80 |
Volume | |
Avg. volume | 4,619,085 |
Market cap | 4.565B |
Beta (5Y monthly) | 1.58 |
PE ratio (TTM) | N/A |
EPS (TTM) | -17.51 |
Earnings date | 03 Aug 2022 - 08 Aug 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 183.40 |
Novavax (NASDAQ: NVAX) investors are no strangers to tragedy. On Feb. 9 in 2021, shares of the coronavirus vaccine developer hit their all-time high of $331.68. Are longtime shareholders doomed to heavy losses forever, or will Novavax return to its glory days?
A turbulent market didn't scare successful money managers away from buying shares in these fast-paced companies.
Novavax disappointed investors when its regulatory submissions fell behind. Now, all eyes are on Novavax's next step: winning authorization in the U.S. Could this nudge the stock out of its slump -- and even turn it into a multibagger? Novavax reported revenue of $704 million and net income of $203 million.